New gene panel enhances brain tumor profiles
Answers from the Lab
Molecular biomarkers were recently added to the World Health Organization's classification of brain tumors. In this test specific episode of the "Answers From the Lab" podcast, Cristiane (Cris) Ida, M.D., explains how Mayo Clinic Laboratories' updated neuro-oncology gene panel reflects those changes and yields more clinically relevant information for managing adult and pediatric brain tumors.
"We are now able to provide testing that is well-aligned with the new WHO classification," Dr. Ida says. "Our test has high clinical utility both for diagnostic and, in some instances, therapeutic purposes."
The carefully curated NONCP panel includes diagnostically relevant genes that weren't in the prior panel and omits genes that have been shown to lack strong clinical relevance. NONCP's DNA and RNA subpanels provide simultaneous evaluations for genetic mutations, microsatellite instability status, and gene fusions.
"It is a one-stop shop approach that is particularly useful for complex cases," Dr. Ida says. "The field is evolving quickly, with new biomarkers and molecular features being unraveled every day. This new panel is one of the best tests available for clinicians."
Listen to learn more about Mayo Clinic Laboratories' updated neuro-oncology panel.
Note: Podcasts will not playback on Internet Explorer. Please use an alternative web browser, or listen from your mobile device on a preferred listening app.
Pathology report (final or preliminary) at minimum containing the following information must accompany specimen in order for testing to be performed:
This assay requires at least 20% tumor nuclei.
For specimen preparation guidance, see Tissue Requirement for Solid Tumor Next-Generation Sequencing. In this document, the sizes are given as 4 mm x 4 mm x 10 slides as preferred: approximate/equivalent to 144 mm(2) and the minimum as 3 mm x 1 mm x 10 slides: approximate/equivalent to 36 mm(2).
Additional information: Unused unstained slides will not be returned.
Analytic time: 12 to 20 days
Days performed: Monday through Friday
Molecular biomarkers are a critical component in the treatment of adult and pediatric brain tumors. Robert Jenkins, M.D., Ph.D., explains how Mayo Clinic Laboratories' chromosomal microarray provides more comprehensive and accurate tumor analysis compared with other test methods.
Paul Jannetto, Ph.D., and Loralie Langman, Ph.D., discuss Mayo Clinic Laboratories’ new marijuana monitoring evaluation, which identifies metabolites of both delta-9 tetrahydrocannabinol (THC) and delta-8 THC to accurately identify and characterize patients’ marijuana use.